Orchestra BioMed Holdings, Inc. OBIO
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -20.00% | -99.64% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -20.00% | -99.64% | |||
| Cost of Revenue | -21.88% | -37.25% | |||
| Gross Profit | -19.23% | -99.75% | |||
| SG&A Expenses | -8.54% | -12.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.16% | -8.18% | |||
| Operating Income | -1.27% | -426.86% | |||
| Income Before Tax | -14.81% | -431.32% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -14.81% | -431.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -14.81% | -431.32% | |||
| EBIT | -1.27% | -426.86% | |||
| EBITDA | -1.25% | -421.62% | |||
| EPS Basic | -14.37% | -441.16% | |||
| Normalized Basic EPS | -2.01% | -462.70% | |||
| EPS Diluted | -14.37% | -441.16% | |||
| Normalized Diluted EPS | -2.01% | -462.70% | |||
| Average Basic Shares Outstanding | 1.74% | 1.22% | |||
| Average Diluted Shares Outstanding | 1.74% | 1.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||